mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.071 |
0.04 |
mRNA |
CCT007093 |
GDSC1000 |
pan-cancer |
AAC |
-0.078 |
0.04 |
mRNA |
SN-38 |
GDSC1000 |
pan-cancer |
AAC |
0.075 |
0.04 |
mRNA |
MPS-1-IN-1 |
GDSC1000 |
pan-cancer |
AAC |
0.072 |
0.04 |
mRNA |
GSK-1904529A |
GDSC1000 |
pan-cancer |
AAC |
-0.075 |
0.04 |
mRNA |
BRD-K16147474 |
CTRPv2 |
pan-cancer |
AAC |
-0.085 |
0.05 |
mRNA |
L-685458 |
CCLE |
pan-cancer |
AAC |
-0.098 |
0.05 |
mRNA |
linifanib |
GDSC1000 |
pan-cancer |
AAC |
-0.076 |
0.05 |
mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.073 |
0.05 |
mRNA |
QS11 |
GDSC1000 |
pan-cancer |
AAC |
-0.076 |
0.05 |